The plasma protein products market continues to experience remarkable growth, with an estimated value of US$ 32.8 billion in 2023, projected to reach US$ 72.9 billion by 2034. This growth translates to a compound annual growth rate (CAGR) of 7.53% from 2024 to 2034. The market’s expansion is driven by several key factors, including the increasing incidences of hematological and autoimmune disorders, growing research and development, and heightened awareness surrounding plasma donation.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5305
Immunoglobulins, plasma proteins injected intravenously, are central to the treatment of various health conditions, particularly autoimmune, infectious, and idiopathic disorders. This segment held the largest market share in 2023, driven by the growing prevalence of these disorders, particularly in the wake of the COVID-19 pandemic. According to a 2023 study by the University of Oxford, approximately one in every ten individuals in the UK is affected by an autoimmune disorder, with incidences increasing significantly post-pandemic. This surge has amplified the demand for immunoglobulin therapies, which work to bolster the immune system and manage chronic health conditions.
As the demand for immunoglobulin treatments rises, supported by advancements in manufacturing processes and a deeper understanding of the role these proteins play in disease management, the segment is expected to continue growing at a rapid pace. Immunoglobulin therapies remain essential for treating various autoimmune and infectious diseases, with increasing patient populations fueling continued market growth.
Alongside immunoglobulins, the albumin segment is set for substantial growth in the coming years. Albumin is a vital plasma protein used to treat conditions like shock, blood loss, burns, and surgery recovery by increasing the blood plasma volume. The growing incidence of these conditions, coupled with the rising preference for natural product therapeutics, is propelling the demand for albumin-based treatments.
Albumin is gaining attention not only for its role in critical care but also for its use in other therapeutic areas such as nephrology and oncology. As the population ages and the prevalence of conditions requiring albumin therapy rises, this segment’s growth trajectory looks promising. The expanding use of natural treatments, along with a growing focus on plasma-derived therapies, further enhances albumin’s market potential.
In terms of application, the hospital segment accounted for the largest share of the plasma protein products market in 2023. Hospitals remain the primary setting for the administration of plasma protein therapies, as they offer the infrastructure, trained medical personnel, and capital investment needed for safe and effective plasma storage and administration. Hospitals are particularly critical in managing patients with severe conditions such as bleeding emergencies, autoimmune diseases, and chronic illnesses, where plasma proteins like immunoglobulins and albumin are commonly used.
The growing number of patients requiring intensive care, along with the increasing prevalence of conditions that necessitate plasma protein therapies, further strengthens the demand for these products in hospitals. Favorable reimbursement policies and the availability of trained healthcare providers also contribute to the segment’s growth. As a result, hospitals continue to be the dominant end-user of plasma protein products, playing a central role in the ongoing market expansion.
The increasing awareness surrounding plasma donation is also helping to fuel market growth. As more individuals become aware of the life-saving potential of plasma donation, the supply of plasma proteins is expected to rise, supporting market growth. Additionally, the growing emphasis on research and development in the field of plasma protein therapies is driving innovation, with new treatments emerging to address a wider range of conditions.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/plasma-protein-products-market-sizing
Access exclusive insight now @ https://www.towardshealthcare.com/price/5305
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
The global thyroid cancer diagnostics market is experiencing steady growth as advancements in medical technologies continue to enhance early detection,… Read More
The global autoimmune disease diagnostics market is poised for significant growth in the coming decade. Market forecasts indicate a surge… Read More
The Europe dermal filler market is witnessing remarkable growth, fueled by rising beauty consciousness, advancements in non-invasive aesthetic procedures, and… Read More
The AI in cancer drugs market is on a remarkable growth path, poised to generate substantial revenue between 2025 and… Read More
The global biostimulants market is on a steady rise. Valued at USD 3.06 billion in 2024, it's expected to grow… Read More
The dental insurance market is booming. In 2024, it was valued at $232.07 billion, grew to $253.72 billion in 2025,… Read More